US 8501766
Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate
granted A61KA61K31/4704A61K31/519
Quick answer
US patent 8501766 (Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate) held by TEVA PHARMACEUTICAL INDUSTRIES, LTD. expires Mon Aug 01 2033 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- TEVA PHARMACEUTICAL INDUSTRIES, LTD.
- Grant date
- Tue Aug 06 2013 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Aug 01 2033 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 10
- CPC classes
- A61K, A61K31/4704, A61K31/519, A61P, A61P19/00